# A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

> **NCT02672501** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai GeneChem Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Leukemia, B-Cell

## Interventions

- **DRUG:** anti-CD19-CAR-T cells

## Key facts

- **NCT ID:** NCT02672501
- **Lead sponsor:** Shanghai GeneChem Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2018-06
- **Final completion:** 2019-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672501, "A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02672501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*